Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling
Phytotherapy Research · 2023-05 · 37 (5) · 1839-1849
DOI: 10.1002/ptr.7701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 13.12.2022. Verfasst von Zhen Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Cardiomegaly, Toll-Like Receptor 4. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Salidroside, a prominent active ingredient in traditional Chinese medicines, is garnering increased attention because of its unique pharmacological effects against ischemic heart disease via MAPK signaling, which plays a critical role in regulating the evolution of ventricular hypertrophy. However, the function of Salidroside on myocardial hypertrophy has not yet been elucidated. C57BL/6 mice were subjected to transverse aortic constriction (TAC), and treated with Salidroside (100 mg kg −1 day −1 ) by oral gavage for 3 weeks starting 1 week after surgery. Four weeks after TAC surgery, the mice were subjected to echocardiography and then sacrificed to harvest the hearts for analysis. For in vitro study, neonatal rat cardiomyocytes were used to validate the protective effects of Salidroside in response to Angiotensin II (Ang II, 1 μM) stimulation. Here, we proved that Salidroside dramatically inhibited hypertrophic reactions generated by pressure overload and isoproterenol (ISO) injection. Salidroside prevented the activation of the TAK1‐JNK/p38 axis. Salidroside pretreatment of TAK1‐inhibited cardiomyocytes shows no additional attenuation of Ang II‐induced cardiomyocytes hypertrophy and signaling pathway activation. The overexpression of constitutively active TAK1 removed the protective effects of Salidroside on myocardial hypertrophy. TAC‐induced increase of TLR4 protein expression was reduced considerably in the Salidroside treated mice. Transient transfection of small interfering RNA targeting TLR4 (siTLR4) in cardiomyocytes did not further decrease the activation of the TAK1/JNK‐p38 axis. In conclusion, Salidroside functioned as a TLR4 inhibitor and displayed anti‐hypertrophic action via the TAK1/JNK‐p38 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
- Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, People's Republic of China.
ORCID-Profile: Qi-Zhu Tang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, Z., Liu, F. Y., Yang, D., Wang, M. Y., Li, C. F., Tang, N., Ma, S. Q., An, P., Yang, Z., & Tang, Q. Z. (2023). Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling. Phytotherapy Research, 37(5), 1839-1849. https://doi.org/10.1002/ptr.7701
Vancouver
Guo Z, Liu FY, Yang D, Wang MY, Li CF, Tang N, et al. Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling. Phytotherapy Research. 2023;37(5):1839-1849. doi:10.1002/ptr.7701
BibTeX
@article{Guo2023,
author = {Guo, Zhen and Liu, Fang-Yuan and Yang, Dan and Wang, Ming-Yu and Li, Chen-Fei and Tang, Nan and Ma, Shu-Qing and An, Peng and Yang, Zheng and Tang, Qi-Zhu},
title = {Salidroside ameliorates pathological cardiac hypertrophy via TLR4‐TAK1 ‐dependent signaling},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {5},
pages = {1839--1849},
doi = {10.1002/ptr.7701}
}
EUVIMED